Boundless Bio Inc. (BOLD), a San Diego-based clinical-stage oncology company, Monday announced the appointment of Robert Doebele as Chief Medical Officer.
The company has been advancing its BBI-355 Phase 1/2 POTENTIATE trial and prepares to select a development candidate for its Kinesin program.
Doebele brings extensive experience in precision oncology, having co-founded Rain Oncology, Inc., where he had previously served as Chief Scientific and Medical Officer.
BOLD is currently trading at $2.31 up 0.87 percent or $0.02 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.